BioTuesdays

Tag - HTBX

Heat Biologics
Markets

Cantor starts Heat Biologics at OW; PT $22

Cantor Fitzgerald initiated coverage of Heat Biologics (NASDAQ:HTBX) with an “overweight” rating and $22 price target. The stock closed at $7.87 on March 2. Heat Biologics is developing proprietary immunotherapy...

March 3, 2021
Heat Biologics
Markets

Maxim ups Heat Biologics PT to $5 from $2

Maxim Group raised its price target for Heat Biologics (NASDAQ:HTBX) to $5 from $2, citing the potential of the company’s vaccine platform to produce long-lasting cellular immunity against COVID-19. The stock closed at...

July 27, 2020
Heat Biologics
Markets

Maxim starts Heat Biologics at buy; PT $1

Maxim Group launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and price target of $1. The stock closed at 26 cents on Feb. 5. Heat is developing lead asset, ImPACT, a cell-based immune therapy for...

February 6, 2020
Heat Biologics
Markets

Brookline starts Heat Biologics at buy; PT $8

Brookline Capital Markets launched coverage of Heat Biologics (NASDAQ:HTBX) with a “buy” rating and $8 price target. The stock closed at 52 cents on July 29. Heat Biologics has cell-therapy platforms called ImPACT and...

July 30, 2019
Feature

Heat Biologics readies proof-of-concept studies

By Len Zehr After a successful $27-million IPO in the summer, Heat Biologics (NASDAQ:HTBX) plans to begin two proof-of-concept trials later this year of its platform to transform living cancer cells into pumps that...

October 22, 2013